Metabolism of 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 in humans.
Tritium-labeled 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 was administered by intravenous injection into humans. The initial half-life in plasma was determined to be about 3 min. About 35% of the injected radioactivity was excreted in the urine and about 55% in the feces. Twenty-three urinary metabolites were identified. The metabolites included beta-oxidized and omega-oxidized products as well as metabolites in which the 9-methylene group had been biotransformed.
D015064:16,16-Dimethylprostaglandin E2 / Q000031:analogs & derivatives / Q000378:metabolism*; D000596:Amino Acids / Q000032:analysis; D001711:Biotransformation; D055598:Chemical Phenomena; D002621:Chemistry; D005243:Feces / Q000032:analysis; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D006868:Hydrolysis; D007700:Kinetics; D008297:Male; D010084:Oxidation-Reduction; D011459:Prostaglandins E, Synthetic / Q000378:metabolism*; D013997:Time Factors
D000596:Amino Acids; D011459:Prostaglandins E, Synthetic; C025505:meteneprost; D015064:16,16-Dimethylprostaglandin E2